Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration.

@article{KubickaTrzska2014CirculatingAA,
  title={Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration.},
  author={Agnieszka Kubicka-Trząska and Joanna Wilańska and Bożena Romanowska-Dixon and Marek Sanak},
  journal={Acta ophthalmologica},
  year={2014},
  volume={92 8},
  pages={
          e610-4
        }
}
PURPOSE To determine changes in anti-retinal antibodies (ARAs) during anti-VEGF therapy in patients with exudative age-related macular degeneration (AMD) and to assess the correlations between ARAs and disease activity. METHODS The study comprised 98 patients treated with intravitreal bevacizumab. The ophthalmic examination included best corrected visual acuity (BCVA), slit lamp biomicroscopy, fundoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). Serum ARAs levels… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Circulating antiretinal antibodies predict the outcome of anti - VEGFtherapy inpatientswith exudative age - relatedmacular degeneration

  • S Lacroix-Desmazes, SV Kaveri, L Mouthon, A Ayouba, A Coutinho, Kazatchkine
  • 2012

Role of pigment epithelial cells in immune privilege

  • S Sugita
  • Arch Immunol Ther Exp
  • 2009
1 Excerpt